

PA Criteria	Criteria Details						
Covered Uses (FDA approved indication)	Evkeeza is an angiotensin-like 3 (ANGPTL3) inhibitor indicated as an adjunct to other low-density lipoprotein-cholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients, 5 years of age and older, with homozygous familial hypercholesterolemia (HoFH). It is a recombinant human monoclonal antibody that binds to and inhibits ANGPTL3, a member of the angiotensin-like protein family that is expressed primarily in the liver and plays a role in the regulation of lipid metabolism. Evinacumab-dgnb reduces LDL-C independent of the presence of LDL receptor (LDLR) by promoting very low-density lipoprotein (VLDL) processing and clearance upstream of LDL formation. Patients with HoFH often have mutations in the LDLR gene, encoding for the LDL receptor (LDLR).						
Exclusion Criteria	None.						
Required Medical Information	Medical records supporting the request, including documentation of prior therapies and responses to treatment must be provided.						
Age Restriction	None.						
Prescriber Restrictions	None.						
Coverage Duration	Two years. Dose will be approved according to the FDA-approved labeling or within accepted standards of medical practice.						
Other Criteria/Information	Refer to the Gold Coast Health Plan Medicare Part B Reference and Summary of Evidence document. <table border="1" data-bbox="496 1087 1511 1266"> <thead> <tr> <th>HCPCS</th> <th>Description</th> <th>Billing Units/How Supplied</th> </tr> </thead> <tbody> <tr> <td>J1305</td> <td>Evkeeza (evinacumab-dgnb)</td> <td>Billing unit: 5 mg 345 mg/2.3 mL, 1200 mg/8 mL SDV</td> </tr> </tbody> </table>	HCPCS	Description	Billing Units/How Supplied	J1305	Evkeeza (evinacumab-dgnb)	Billing unit: 5 mg 345 mg/2.3 mL, 1200 mg/8 mL SDV
HCPCS	Description	Billing Units/How Supplied					
J1305	Evkeeza (evinacumab-dgnb)	Billing unit: 5 mg 345 mg/2.3 mL, 1200 mg/8 mL SDV					

STATUS	DATE REVISED	REVIEW DATE	APPROVED/REVIEWED BY	EFFECTIVE DATE
Created	3/26/2025	3/26/2025	Dawn Shojai, PharmD, Senior Pharmacy Benefit Consultant (PSG)	N/A
Approved	N/A	8/21/2025	Pharmacy & Therapeutics (P&T) Committee	8/21/2025